Research from Wageningen University & Research (WUR) in the Netherlands has successfully resurrected ancient cannabis enzymes, revealing new opportunities for drug development. This groundbreaking study elucidates how cannabis evolved to produce key bioactive compounds, including tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabichromene (CBC).
The study highlights the evolutionary journey of these compounds, shedding light on how modern cannabis varieties synthesize cannabinoids. The research team employed a technique called ancestral sequence reconstruction, which enables the regeneration of ancient proteins from existing genetic data. By doing so, they were able to recreate cannabinoid-producing enzymes that existed millions of years ago.
Insights into Cannabinoid Production
The findings indicate that ancient enzymes operated differently compared to their modern counterparts. Unlike today’s specialized enzymes, which produce specific cannabinoids, these ancestral versions were more versatile. They could generate multiple compounds from a single precursor, including THC, CBD, and CBC.
According to Robin van Velzen, a leading researcher in the study, “What once seemed evolutionarily ‘unfinished’ turns out to be highly useful.” This flexibility makes these enzymes appealing for new applications in biotechnology and pharmaceutical research.
Particularly noteworthy is the potential of CBC. Although research has primarily focused on THC and CBD, CBC is gaining attention for its possible health benefits. Modern cannabis plants typically contain less than 1% CBC, complicating its study and production. Van Velzen noted, “At present, there is no cannabis plant with a naturally high CBC content,” suggesting that introducing the ancient enzyme into cannabis plants could lead to innovative medicinal varieties.
Implications for Biotechnology and Drug Development
Preliminary studies have indicated that CBC may possess anti-inflammatory, anticonvulsant, and antibacterial properties. However, it remains less studied than THC or CBD. The research team also discovered that the resurrected enzymes were simpler to produce in microorganisms, such as yeast cells, compared to modern enzymes. This advancement allows for the possibility of synthesizing rare cannabinoids efficiently, without the need for extensive plant cultivation.
The team explained, “Through rational engineering of these ancestors, we designed hybrid enzymes which allowed identifying key amino acid mutations underlying the functional evolution of cannabinoid oxidocyclases.” These ancestral and hybrid enzymes displayed unique activities and proved easier to produce heterologously than their contemporary counterparts.
This study, published in the Plant Biotechnology Journal, significantly contributes to understanding the origin and evolution of cannabinoid oxidocyclases. It opens new avenues for breeding, biotechnological, and medicinal applications, paving the way for future innovations in cannabis-derived medications.
As research continues to explore the therapeutic potential of cannabinoids, the resurrection of these ancient enzymes may play a critical role in unlocking new treatments and enhancing our understanding of cannabis as a medicinal plant.
